Edition:
United Kingdom

ACADIA Pharmaceuticals Inc (ACAD.OQ)

ACAD.OQ on NASDAQ Stock Exchange Global Select Market

22.00USD
9:00pm BST
Change (% chg)

$0.24 (+1.10%)
Prev Close
$21.76
Open
$21.23
Day's High
$22.61
Day's Low
$20.97
Volume
1,283,186
Avg. Vol
955,475
52-wk High
$38.00
52-wk Low
$12.80

Latest Key Developments (Source: Significant Developments)

FDA Says Finds No New Or Unexpected Safety Risks Associated With Nuplazid
Thursday, 20 Sep 2018 

Sept 20 (Reuters) - U.S. Food and Drug Administration::FDA - FINDS NO NEW/UNEXPECTED SAFETY RISKS ASSOCIATED WITH NUPLAZID, A MEDICATION TO TREAT HALLUCINATIONS, DELUSIONS OF PARKINSON’S DISEASE PSYCHOSIS.FDA- CONCLUSION REMAINS UNCHANGED THAT NUPLAZID'S BENEFITS OUTWEIGH ITS RISKS FOR PATIENTS WITH HALLUCINATIONS&DELUSIONS OF PARKINSON’S DISEASE PSYCHOSIS.FDA - RISK OF QT PROLONGATION AND SERIOUS ARRHYTHMIA ASSOCIATED WITH NUPLAZID IS NOTED IN WARNINGS AND PRECAUTIONS SECTION OF DRUG LABEL.FDA - SOME POTENTIALLY CONCERNING PRESCRIBING PATTERNS WERE OBSERVED ASSOCIATED WITH NUPLAZID.  Full Article

Acadia Pharmaceuticals Q2 Loss Per Share $0.51
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.51.Q2 SALES $57.1 MILLION VERSUS I/B/E/S VIEW $58.6 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.45 -- THOMSON REUTERS I/B/E/S.LOWERING ITS 2018 NUPLAZID NET SALES GUIDANCE TO BE BETWEEN $210 MILLION AND $225 MILLION.FOR Q3 OF 2018, ACADIA EXPECTS NUPLAZID NET SALES TO BE BETWEEN $52 MILLION AND $59 MILLION.ACADIA PHARMACEUTICALS - LOWERING GUIDANCE FOR ITS YEAR END 2018 CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES TO BE BETWEEN $155 MILLION TO $170 MILLION.  Full Article

Acadia Pharmaceuticals posts Q3 loss of $0.53 per share
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Acadia Pharmaceuticals Inc :Acadia Pharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $0.53.Q3 sales $35.6 million versus I/B/E/S view $32 million.Sees FY 2017 sales $124 million to $127 million.Q3 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Acadia Pharmaceuticals Q1 Loss Per Share $0.44

* ACADIA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS